Chargement en cours...
Gene therapy for ADA‐SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products
Gene and cell therapy research recently reached a fundamental milestone toward the goal to deliver new medicines for orphan diseases. In 2016, the European Commission granted market approval to GlaxoSmithKline (GSK) for ex vivo hematopoietic stem cell (HSC) gene therapy for the treatment of adenosin...
Enregistré dans:
| Publié dans: | EMBO Mol Med |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5452047/ https://ncbi.nlm.nih.gov/pubmed/28396566 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201707573 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|